L20 at #ACR23 Phase 3 RCT of #Telitacicept vs. placebo in #RA ☝🏻B-cell neutralization by targeting BlyS and APRIL ✅ better ACR20 and 50 response at W24 ✅ favorable structural response ✅ good safety profile ❓ few seronegative patients A new small molecule to treat #RA? PAJ https://t.co/fyrqAya41e